Lung cancer combo trial ends early after enrolling only 5 patients

NCT ID NCT05141357

Terminated Disease control Sponsor: HUYABIO International, LLC. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 13 times

Summary

This study tested a new drug (HBI-8000) combined with an approved immunotherapy (pembrolizumab) for people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and effective. The trial was stopped early and only enrolled 5 adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CBCC Global Research, Inc at Comprehensive Blood and Cancer Center

Bakersfield, California, 93309, United States
Cotton O'Neil Clinical Research Center

Topeka, Kansas, 66606, United States
Frederick Health-JMSCI

Frederick, Maryland, 21702, United States
Hematology Oncology Associates Of The Treasure Coast

Port Saint Lucie, Florida, 34952, United States
Midewestern Regional Medical Center, LLC

Zion, Illinois, 60099, United States
Southeastern Regional Medical Center

Newnan, Georgia, 30265, United States
Western Regional Medical Center

Goodyear, Arizona, 85338, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER